NCT06168955

Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)

Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Central Hospital, Nancy, France · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction. This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
OTHER	skin biopsy	skin biopsy for cell culture and N-homocysteinylation study

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2023-12-13
• Last updated: 2024-01-05

Locations

1 site across 1 country: France